用一种代谢干预来评估2型糖尿病的缓解,包括固定比例胰岛素脱格卢迪克和利拉格卢提德:一种随机对照试验
Zubin Punthakee1,2, Stephanie Hall2, Natalia McInnes1,2
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Diabetes, obesity & metabolism
|September 6, 2024
概括
一项密集的干预措施在一年内降低了2型糖尿病复发风险,但没有实现持续缓解. 这项研究强调了糖尿病管理和复发预防的潜在益处.
科学领域:
- 代谢性疾病研究研究.
- 临床试验方法论 临床试验方法论
- 糖尿病治疗方法 糖尿病治疗方法
背景情况:
- 2型糖尿病 (T2D) 缓解是治疗的关键目标.
- 短期的密集干预措施显示出有希望的结果,但需要进一步评估.
- 了解复发模式对于长期的T2D管理至关重要.
研究的目的:
- 评估16周强化代谢干预对T2D缓解的影响.
- 为了评估教练,甲福明和胰岛素脱代克/利拉格卢提德对T2D缓解的影响.
- 为了确定持续缓解率和干预后复发风险.
主要方法:
- 进行了一项多中心,开放标签,随机对照试验.
- 在T2D诊断后5年内先前未服用胰岛素的参与者被随机分类.
- 干预组接受了16周的密集指导和药物治疗,随后是1年的观察期.
主要成果:
- 16周后,干预参与者显示HbA1c显著降低 (40 vs. 51 mmol/mol),体重减轻 (3.3% vs. 1.9%) 更大.
- 在干预组中观察到糖尿病复发风险降低 (HR 0.63,p=0.007).
- 持续缓解率在干预后12周或52周之间没有显著差异.
结论:
- 密集的缓解诱导干预,包括固定比例的胰岛素德格卢迪克/利拉格卢提德,在一年内降低了T2D复发的风险.
- 通过这种短期密集治疗方法,无法实现持续的糖尿病缓解.
- 需要进一步的研究来优化对长期T2D缓解的干预措施.
相关概念视频
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Insulin: Dosing Regimen and Adverse Effects
160
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
160
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K


